# HUTCHMED HUTCHMED is an Asset Manager based in Hong Kong, China. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Hong Kong, China - **Region:** Asia - **Address:** Hong Kong - **Founded:** 2000 - **Assets under management:** Undisclosed - **Website:** hutch-med.com ## Regulatory record - **Reports private funds:** No ## About HUTCHMED was founded in 2000 as an innovative biopharmaceutical division within the CK Hutchison conglomerate, with Weiguo Su appointed to steer the scientific vision. The firm's wealth engine originates from its majority owner, the Hong Kong-based multinational CK Hutchison Holdings, which provides both patient capital and a strategic umbrella. This structural backing allows HUTCHMED to pursue deep, long-cycle drug discovery while maintaining an independent scientific identity and public listing on the Hong Kong, London, and Nasdaq exchanges. The firm's strategy centers on a proprietary discovery engine targeting highly validated pathways with difficult-to-drug molecular profiles. Deployment focuses on late-stage clinical development — it has advanced three internally discovered oncology drugs to global approvals: fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors, and savolitinib for MET exon 14 skipping non-small cell lung cancer. Geographic deployment flows predominantly through clinical sites in China and the United States, with a commercial sales force handling hospital distribution across mainland China and licensing partners like Takeda managing global commercial rights for select assets. The pipeline also extends to autoimmune and inflammatory disease targets. In November 2023, Takeda received US FDA approval for fruquintinib, triggering a multi-million dollar milestone payment and marking the first global FDA nod for a HUTCHMED-discovered drug (per the firm, November 2023). The firm operates research headquarters in Shanghai and maintains a retail pharmacy joint venture, Hutchison Sinopharm, originally built to distribute branded drugs in China. While headcount is not disclosed as a standalone asset manager, HUTCHMED functions with a hybrid corporate structure, housing more than a thousand employees under a single listed entity. Structurally, HUTCHMED sits apart from virtually every other Chinese biotech. It is neither a contract research organization nor a pure venture-capital creation; it functions as a revenue-generating, publicly traded pharmaceutical entity inside a century-old industrial conglomerate. This gives it a balance sheet capable of absorbing R&D misses — its 2023 R&D spend exceeded $300 million — while avoiding the binary financing risk that kills most single-asset biotechs. The conglomerate parentage and triple-listing structure provide liquidity paths uncommon for drug developers of its scale. ## Sectors - Biotech & Pharmaceuticals ## People - Simon To — Chairman - Weiguo Su — Chief Executive Officer and Chief Scientific Officer - Johnny Cheng — Chief Financial Officer ## Questions ### Who runs investment decisions at HUTCHMED? HUTCHMED is not a fund; it is an operating biopharmaceutical company. Scientific investment decisions are driven by Chief Executive Officer and Chief Scientific Officer Weiguo Su, who has led the discovery engine since founding. The board of directors, chaired by Simon To and including representatives from majority owner CK Hutchison Holdings, governs strategic capital allocation. Major licensing decisions, such as the fruquintinib deal with Takeda, are executed by the management team and approved by the board. ### How does HUTCHMED source its drug candidates? All of HUTCHMED's clinical drug candidates are internally discovered through a proprietary oncology and immunology research platform based in Shanghai. The firm specifically targets validated but intractable oncogenic drivers like MET, VEGFR, FGFR, and Syk. It does not in-license early-stage assets, making its pipeline wholly-owned. ### Does HUTCHMED participate in fund commitments or only direct deals? HUTCHMED does not commit capital to external funds. Its capital deployment is entirely directed toward its own internal research and development programs, clinical trials, and the commercial infrastructure required to distribute its approved drugs in China. It acts as an operating company, not an allocator. ### What is HUTCHMED's known posture on strategic partnerships versus wholly-owned programs? HUTCHMED pursues regional out-licensing deals for global rights to its wholly-owned assets. Its landmark partnership is the ex-China licensing agreement with Takeda for fruquintinib. This strategy monetizes global rights to fund Chinese development, while the firm retains full ownership of its China commercial rights for the same drug. ### How is HUTCHMED related to Hutchison Sinopharm? Hutchison Sinopharm is a commercial joint venture that HUTCHMED controls, originally built to distribute branded pharmaceuticals from multinational companies across China. It now serves as the primary retail and hospital distribution arm for HUTCHMED's own oncology products within China, providing a controlled go-to-market channel that other Chinese biotechs often lack. ## Related profiles - [Central Puerto](https://altss.com/profile/central-puerto-sa) - [ReNew Energy Global](https://altss.com/profile/renew-energy-global-plc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/hutchmed-china-ltd Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology